Literature DB >> 9746774

Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.

I Martinelli1, P M Mannucci, V De Stefano, E Taioli, V Rossi, F Crosti, K Paciaroni, G Leone, E M Faioni.   

Abstract

Deficiency of the naturally occurring anticoagulant proteins, such as antithrombin, protein C and protein S, and activated protein C resistance due to the factor V Leiden gene mutation is associated with inherited thrombophilia. So far, no direct comparison of the thrombotic risk associated with these genetic defects is available. In this study, we wish to compare the lifetime probability of developing thrombosis, the type of thrombotic symptoms, and the role of circumstantial triggering factors in 723 first- and second-degree relatives of 150 index patients with different thrombophilic defects. We found higher risks for thrombosis for subjects with antithrombin (risk ratio 8.1, 95% confidence interval [CI], 3.4 to 19.6), protein C (7.3, 95% CI, 2.9 to 18.4) or protein S deficiency (8.5, 95% CI, 3. 5 to 20.8), and factor V Leiden (2.2, 95% CI, 1.1 to 4.7) than for individuals with normal coagulation. The risk of thrombosis for subjects with factor V Leiden was lower than that for those with all three other coagulation defects (0.3, 95% CI, 0.1 to 1.6), even when arterial and superficial vein thromboses were excluded and the analysis was restricted to deep vein thrombosis (0.3, 95% CI, 0.2 to 0.5). No association between coagulation defects and arterial thrombosis was found. The most frequent venous thrombotic manifestation was deep vein thrombosis with or without pulmonary embolism (90% in antithrombin, 88% in protein C, 100% in protein S deficiency, and 57% in factor V Leiden), but a relatively mild manifestation such as superficial vein thrombosis was common in factor V Leiden (43%). There was a predisposing factor at the time of venous thromboembolism in approximately 50% of cases for each of the four defects. In conclusion, factor V Leiden is associated with a relatively small risk of thrombosis, lower than that for antithrombin, protein C, or protein S deficiency. In addition, individuals with factor V Leiden develop less severe thrombotic manifestations, such as superficial vein thrombosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9746774

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  39 in total

1.  A multi-site study for detection of the factor V (Leiden) mutation from genomic DNA using a homogeneous invader microtiter plate fluorescence resonance energy transfer (FRET) assay.

Authors:  M Ledford; K D Friedman; M J Hessner; C Moehlenkamp; T M Williams; R S Larson
Journal:  J Mol Diagn       Date:  2000-05       Impact factor: 5.568

2.  Internal jugular vein thrombosis associated with venous hypoplasia and protein S deficiency revealed by ultrasonography.

Authors:  Byung Gun Lim; Young Min Kim; Heezoo Kim; Sang Ho Lim; Mi Kyoung Lee
Journal:  J Anesth       Date:  2011-09-20       Impact factor: 2.078

3.  Factor V Leiden mutation does not correlate with retinal vascular occlusion in white patients with Behçet's disease.

Authors:  Y Chen; M R Stanford; G R Wallace; R W Vaughan; E Kondeatis; F Fortune
Journal:  Br J Ophthalmol       Date:  2003-08       Impact factor: 4.638

Review 4.  Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients.

Authors:  Ana T Rocha; Edison F Paiva; Arnaldo Lichtenstein; Rodolfo Milani; Cyrillo Filho Cavalheiro; Francisco H Maffei
Journal:  Vasc Health Risk Manag       Date:  2007

Review 5.  Thrombolysis in antiphospholipid syndrome: current hematologic perspectives.

Authors:  René Y McNall-Knapp
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

Review 6.  The impact of inherited thrombophilia on surgery: a factor to consider before transplantation?

Authors:  Elias Kfoury; Ali Taher; Said Saghieh; Zaher K Otrock; Rami Mahfouz
Journal:  Mol Biol Rep       Date:  2008-05-31       Impact factor: 2.316

Review 7.  The use of direct oral anticoagulants in inherited thrombophilia.

Authors:  Jessica W Skelley; C Whitney White; Angela R Thomason
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

8.  Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C.

Authors:  Iman Zandieh; Mohamed Adenwalla; Cindy Cheong-Lee; Patrick E Ma; Eric M Yoshida
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

9.  Assessment of specific risks for the recurrence of deep vein thrombosis: a case report.

Authors:  Joshua A Boys; Christine J Medaugh; Houria I Hassouna
Journal:  Cases J       Date:  2009-08-24

10.  Thrombophilia: 2009 update.

Authors:  Pat Foy; Stephan Moll
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.